| Literature DB >> 29434923 |
Kamran Harati1, Jonas Kolbenschlag1, Jens Bohm1, Hiltrud Niggemann2, Hamid Joneidi-Jafari1, Ingo Stricker3, Marcus Lehnhardt1, Adrien Daigeler1.
Abstract
Data on prognostic factors and treatment outcomes for chest wall soft tissue sarcomas (STS) are sparse. Wide resections with negative margins are the mainstay of therapy, but the prognostic impact of surgical margins remains controversial. The purpose of the present study was to determine the significance of microscopic margins through a long-term follow-up. The associations between local recurrence-free survival (LRFS), overall survival (OS) and potential prognostic factors were retrospectively assessed in a consecutive series of 110 patients who were suitable for surgical treatment with curative intent. Potential prognostic factors were assessed using univariate and multivariate analyses. The median follow-up time following primary diagnosis was 9.6 years [95% confidence interval (CI), 7.2-10.5]. In the entire cohort, the 5-year estimates of the OS and LRFS rates were 66.0% (95% CI, 55.9-74.3) and 60.6% (95% CI, 50.3-69.4), respectively. A total of 27 patients (24.5%) developed distant metastases with a median survival time of 0.9 years following the diagnosis of metastasis. Surgical margins attained at the initial resection and eventual re-excisions significantly influenced OS in univariate analysis (5-year OS, R0 69.9% vs. R1/R2 38.5%; P=0.046), but this failed to reach statistical significance in the multivariate analysis. In the multivariate analysis, significant adverse prognostic features of LRFS included angiosarcoma subtype, G2 and G3 histology. For OS, the only independent significant predictors were age >50 years, tumor size >5 cm, angiosarcoma subtype and G3 histology. The results of the present study suggest that tumor biology, as reflected by the histological grade, influences the final outcome in patients with chest wall STS. Surgical margins failed to reach statistical significance in multivariate analysis as they demonstrated a dependency towards the independent predictors of OS. Subsequently, a positive margin status may be a result rather than a cause of biological aggressiveness, and it may not influence the outcome directly.Entities:
Keywords: chest wall; margin; sarcoma; survival
Year: 2017 PMID: 29434923 PMCID: PMC5777128 DOI: 10.3892/ol.2017.7624
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Results of the univariate analyses to determine factors predictive of LRFS.
| Clinicopathological characteristic | N | No. of local recurrences | 1-year LRFS (95% CI) | 2-year LRFS (95% CI) | 5-year LRFS (95% CI) | P-value (log-rank) |
|---|---|---|---|---|---|---|
| All patients | 110 | 55 | 77.3 (68.1–84.2) | 70.4 (60.6–78.2) | 60.6 (50.3–69.4) | |
| Age, years | 0.116 | |||||
| ≤50 | 39 | 18 | 81.6 (65.3–90.8) | 79.0 (62.4–88.9) | 70.4 (52.9–82.5) | |
| >50 | 71 | 37 | 74.9 (62.7–83.6) | 65.3 (52.4–75.4) | 54.7 (41.5–66.1) | |
| Gender | 0.007 | |||||
| Female | 57 | 35 | 74.1 (60.1–83.8) | 64.3 (49.9–75.6) | 49.2 (34.7–62.2) | |
| Male | 53 | 20 | 80.7 (67.1–89.1) | 76.6 (62.4–86.0) | 72.3 (57.7–82.6) | |
| Tumor size, cm | 0.104 | |||||
| ≤5 | 37 | 17 | 89.1 (73.5–95.8) | 83.4 (66.6–92.2) | 73.9 (55.6–85.6) | |
| >5 | 73 | 38 | 71.0 (58.7–80.2) | 63.4 (50.7–73.6) | 53.4 (40.6–64.7) | |
| Tumor depth | 0.109 | |||||
| Epifascial | 52 | 26 | 87.8 (74.9–94.3) | 81.7 (67.8–90.0) | 71.1 (56.1–81.8) | |
| Subfascial | 58 | 29 | 68.1 (54.3–78.6) | 60.3 (46.1–71.8) | 51.1 (36.6–63.8) | |
| Grading | <0.001[ | |||||
| G1 | 32 | 8 | 100 (−) | 96.8 (79.2–99.5) | 89.5 (70.8–96.5) | |
| G2 | 32 | 18 | 77.4 (58.4–88.5) | 67.3 (47.7–80.9) | 53.5 (34.3–69.3) | |
| G3 | 46 | 29 | 60.7 (44.5–73.5) | 52.8 (36.7–66.6) | 44.1 (28.3–58.8) | |
| Subtype | ||||||
| NOS | 31 | 18 | 64.5 (45.2–78.5) | 57.9 (38.7–73.0) | 57.9 (38.7–73.0) | 0.166 |
| Angiosarcoma | 21 | 17 | 73.7 (47.9–88.1) | 57.9 (33.2–76.3) | 26.3 (9.6–46.8) | <0.001 |
| Liposarcoma | 19 | 4 | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 0.007 |
| Leiomyosarcoma | 10 | 4 | 80.0 (40.9–94.6) | 80.0 (40.9–94.6) | 66.7 (27.2–88.1) | 0.361 |
| Margin status | 0.275 | |||||
| (Primary tumor) | ||||||
| R0 | 96 | 47 | 76.7 (66.8–84.0) | 71.2 (60.8–79.2) | 61.5 (50.6–70.7) | |
| R1/R2 | 14 | 8 | 82.5 (46.1–95.3) | 61.9 (27.0–83.9) | 49.5 (16.9–75.7) | |
| Full-thickness resection received | 0.523 | |||||
| No | 89 | 45 | 80.3 (70.3–87.3) | 71.9 (61.0–80.2) | 62.7 (51.2–72.2) | |
| Yes | 21 | 10 | 64.6 (39.6–81.4) | 64.6 (39.6–81.4) | 52.2 (27.7–72.0) | |
| Wound closure | 0.917 | |||||
| Primary closure | 90 | 46 | 80.5 (70.5–87.4) | 72.0 (61.2–80.3) | 63.1 (51.7–72.5) | |
| Plastic surgical tissue transfer | 20 | 9 | 63.3 (38.1–80.6) | 63.3 (38.1–80.6) | 47.5 (22.1–69.3) | |
| Adjuvant radiotherapy received (Primary tumor) | 0.799 | |||||
| No | 73 | 38 | 77.0 (65.3–85.3) | 72.6 (60.5–81.6) | 61.2 (48.4–71.8) | |
| Yes | 37 | 17 | 78.2 (61.1–88.5) | 65.9 (47.7–79.1) | 59.5 (41.1–73.8) | |
| Adjuvant chemotherapy received (Primary tumor) | 0.519 | |||||
| No | 96 | 47 | 78.2 (68.3–85.4) | 71.4 (60.8–79.5) | 63.8 (52.7–72.9) | |
| Yes | 14 | 8 | 71.4 (40.6–88.2) | 63.5 (33.1–83.0) | 39.7 (14.8–64.0) |
Global log-rank test for trend of survivor functions. LRFS, local recurrence-free survival; CI, confidence interval; NOS, sarcoma not otherwise specified.
Results of the univariate analyses to determine factors predictive of OS.
| Clinicopathological characteristic | N | No. of mortalities | 1-year OS (95% CI) | 2-year OS (95% CI) | 5-year OS (95% CI) | P-value (log-rank) |
|---|---|---|---|---|---|---|
| All patients | 110 | 44 | 90.7 (83.3–94.9) | 80.0 (71.0–86.5) | 66.0 (55.9–74.3) | |
| Age, years | 0.003 | |||||
| ≤50 | 39 | 8 | 94.8 (80.8–98.7) | 89.4 (74.1–95.9) | 80.9 (64.0–90.4) | |
| >50 | 71 | 36 | 88.3 (77.9–94.0) | 74.6 (62.3–83.4) | 57.6 (44.7–68.5) | |
| Gender | 0.267 | |||||
| Female | 57 | 25 | 87.1 (74.8–93.6) | 75.6 (61.7–85.1) | 59.5 (44.8–71.5) | |
| Male | 53 | 19 | 94.3 (83.5–98.1) | 84.5 (71.4–91.9) | 72.5 (58.0–82.7) | |
| Tumor size, cm | 0.022 | |||||
| ≤5 | 37 | 10 | 94.6 (80.1–98.6) | 89.2 (73.7–95.8) | 80.5 (63.3–90.2) | |
| >5 | 73 | 34 | 88.6 (78.5–94.1) | 75.0 (62.8–83.7) | 58.0 (45.2–68.8) | |
| Tumor depth | 0.098 | |||||
| Epifascial | 52 | 18 | 96.0 (85.1–99.0) | 86.0 (72.9–93.1) | 75.6 (60.9–85.3) | |
| Subfascial | 58 | 26 | 85.9 (73.8–92.7) | 74.6 (60.8–84.1) | 57.3 (43.0–69.3) | |
| Grading | 0.003[ | |||||
| G1 | 32 | 7 | 100 (−) | 100 (−) | 88.9 (69.3–96.3) | |
| G2 | 32 | 13 | 87.5 (70.0–95.1) | 84.3 (66.2–93.1) | 64.0 (44.4–78.3) | |
| G3 | 46 | 24 | 86.3 (72.0–93.6) | 62.3 (46.0–75.0) | 50.3 (34.5–64.2) | |
| Subtype | ||||||
| NOS | 31 | 18 | 64.5 (45.2–78.5) | 57.9 (38.7–73.0) | 57.9 (38.7–73.0) | 0.166 |
| Angiosarcoma | 21 | 17 | 73.7 (47.9–88.1) | 57.9 (33.2–76.3) | 26.3 (9.6–46.8) | <0.001 |
| Liposarcoma | 19 | 4 | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 0.007 |
| Leiomyosarcoma | 10 | 4 | 80.0 (40.9–94.6) | 80.0 (40.9–94.6) | 66.7 (27.2–88.1) | 0.361 |
| Margin status (Primary tumor) | 0.046 | |||||
| R0 | 96 | 36 | 92.5 (85.0–96.4) | 82.6 (73.1–88.9) | 69.9 (59.2–78.3) | |
| R1/R2 | 14 | 8 | 76.9 (44.2–91.9) | 61.5 (30.8–81.8) | 38.5 (14.1–62.8) | |
| Full-thickness resection | 0.025 | |||||
| No | 89 | 32 | 96.5 (89.6–98.9) | 84.5 (74.7–90.7) | 70.7 (59.5–79.3) | |
| Yes | 21 | 12 | 66.7 (42.5–82.5) | 61.9 (38.1–78.8) | 46.4 (24.4–65.9) | |
| Wound closure | 0.352 | |||||
| Primary closure | 90 | 35 | 94.3 (86.9–97.6) | 82.5 (72.7–89.1) | 68.0 (56.9–76.9) | |
| Plastic surgical tissue transfer | 20 | 9 | 73.7 (47.9–88.1) | 68.4 (42.8–84.4) | 55.8 (30.2–75.2) | |
| Adjuvant radiotherapy received (Primary tumor) | 0.383 | |||||
| No | 73 | 27 | 90.0 (80.2–95.1) | 79.8 (68.3–87.5) | 70.5 (58.0–79.9) | |
| Yes | 37 | 17 | 91.9 (76.9–97.3) | 80.4 (63.2–90.2) | 57.4 (39.6–71.8) | |
| Adjuvant chemotherapy received (Primary tumor) | 0.479 | |||||
| No | 96 | 37 | 89.3 (81.0–94.1) | 80.4 (70.7–87.2) | 66.6 (55.7–75.3) | |
| Yes | 14 | 7 | 100 (−) | 76.9 (44.2–91.9) | 61.5 (30.8–81.8) |
Global log-rank test for trend of survivor functions. OS, overall survival; CI, confidence interval; NOS, sarcoma not otherwise specified.
Figure 1.Estimated overall survival curves following primary diagnosis according to (A) age and (B) tumor size.
Figure 2.Estimated overall survival curves following primary diagnosis according to (A) histological grade and (B) margin status.
Results of multivariate analysis on LRFS according to Cox's proportional hazards model.
| Category: (reference) | Hazard ratio for recurrence | 95% confidence interval | P-value |
|---|---|---|---|
| Gender: Female (vs. male) | 1.16 | 0.58–2.30 | 0.679 |
| Histological grade: G2 (vs. G1) | 2.65 | 1.15–6.11 | 0.022 |
| Histological grade: G3 (vs. G1) | 3.99 | 1.86–8.54 | <0.001 |
| Histological subtype: Angiosarcoma (vs. other) | 1.96 | 1.02–3.78 | 0.043 |
| Histological subtype: Liposarcoma (vs. other) | 0.36 | 0.10–1.27 | 0.113 |
Results of multivariate analysis on OS according to Cox's proportional hazards model.
| Clinicopathological characteristic: (reference) | Hazard ratio for mortality | 95% confidence interval | P-value |
|---|---|---|---|
| Age: >50 years (vs. ≤50 years) | 2.84 | 1.27–6.39 | 0.011 |
| Margin status: R1/R2 (vs. R0) | 1.50 | 0.62–3.64 | 0.370 |
| Histological grade: G2 (vs. G1) | 1.40 | 0.61–3.20 | 0.423 |
| Histological grade: G3 (vs. G1) | 3.02 | 1.35–6.76 | 0.007 |
| Tumor size: >5 cm (vs. ≤5 cm) | 2.43 | 1.13–5.23 | 0.023 |
| Histological subtype: Angiosarcoma (vs. other) | 2.31 | 1.20–4.44 | 0.012 |
| Full-thickness resection: Yes (vs. no) | 1.59 | 0.66–3.84 | 0.303 |
Overview of retrospective analyses on primary chest wall sarcomas.
| Authors | No. of patients | Median follow-up (months) | Sarcoma type | M (%) | 5-OS (%) | Microscopic margins available | Prognostic effect of microscopic margins on OS | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| Present study | 110 | 65 | STS | 24 | 66 | + | + | |
| Kachroo | 51 | NR | STS/bone/AF | 23 | 66 | + | − | ( |
| Oksuz | 26 | 82 | STS | 42 | 69 | + | − | ( |
| Tsukushi | 44 | 57 | STS | NR | 89 | − | NA | ( |
| Gross | 55 | 52 | STS | 18 | 87 | − | NA | ( |
| Van Geel | 60 | 20 | STS/bone | 48 | 46 | + | − | ( |
| Wouters | 83 | 73 | STS/bone | 25 | 63 | + | NR | ( |
| Gordon | 149 | NA | STS/AF | 35 | 66 | − | NA | ( |
| McMillan | 192 | 51 | STS/AF | 15 | 73 | + | NR | ( |
M, metastasis; 5-OS, 5-year rate of overall survival; AF, aggressive fibromatosis; NR, not reported; NA, data not available; OS, overall survival.